{"title":"低用量ネダプラチン・5FU併用放射線治療が著効した,重度肝障害をともない全身状態不良の肝転移を有する食道癌の1例","authors":"忠久 福井, 伊藤 由理子, 孝志 吉岡, 弘明 武田, 純男 河田","doi":"10.11405/NISSHOSHI.108.813","DOIUrl":null,"url":null,"abstract":"A 64-year-old male visited our hospital complaining of epigastric pain, and was diagnosed as esophageal cancer with multiple liver metastases. Histological examinations revealed squamous cell carcinoma. He had serious liver dysfunctions and his general conditions were severe, expressed as 3 of the performance status. He was treated using radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil after the fully sufficient informed consent was taken. As for adverse events, Grade 2 of thrombocytopenia was only observed. Liver tumors responded to anticancer drug treatment immediately, and liver functions were almost normalized. The chemotherapy using low-dose nedaplatin and 5-FU combined with the radiotherapy was feasible and effective to patients with poor conditions.","PeriodicalId":341053,"journal":{"name":"The Japanese journal of gastro-enterology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2011-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Japanese journal of gastro-enterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11405/NISSHOSHI.108.813","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
A 64-year-old male visited our hospital complaining of epigastric pain, and was diagnosed as esophageal cancer with multiple liver metastases. Histological examinations revealed squamous cell carcinoma. He had serious liver dysfunctions and his general conditions were severe, expressed as 3 of the performance status. He was treated using radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil after the fully sufficient informed consent was taken. As for adverse events, Grade 2 of thrombocytopenia was only observed. Liver tumors responded to anticancer drug treatment immediately, and liver functions were almost normalized. The chemotherapy using low-dose nedaplatin and 5-FU combined with the radiotherapy was feasible and effective to patients with poor conditions.